AKT1 and cancer: Strong interconnection of PI3K-Akt-mTOR with another oncogenic pathway, RAS-RAF-MEK-ERK, the ability to activate MYC oncogene [9,10,11], and “druggability” of the downstream effectors and the adaptor proteins in this cascade make the PI3K-Akt-mTOR pathway an attractive target for cancer treatment.